Literature DB >> 11117292

Inhibitory effects of the quinolone antibiotics trovafloxacin, ciprofloxacin, and levofloxacin on osteoblastic cells in vitro.

P D Holtom1, S A Pavkovic, P D Bravos, M J Patzakis, L E Shepherd, B Frenkel.   

Abstract

We studied the inhibitory effects of the fluoroquinolones levofloxacin, ciprofloxacin, and trovafloxacin on growth and extracellular matrix mineralization in MC3T3-E1 osteoblast-like cell cultures. Levofloxacin had the least inhibitory effect on cell growth, with a 50% inhibitory concentration of approximately 80 microg/ml at 48 and 72 hours. Ciprofloxacin had an intermediate degree of inhibition, with a 50% inhibitory concentration of 40 microg/ml at 48 and 72 hours. Trovafloxacin exerted a profound inhibitory effect on cell growth, with a 50% inhibitory concentration of 0.5 microg/ml, lower than clinically achievable serum levels. The decreased cell counts with up to 2.5 microg/ml of trovafloxacin and with up to 40 microg/ml of ciprofloxacin were not associated with decreased rates of 5-bromo-2'-deoxyuridine incorporation per cell. Alatrovafloxacin, the L-alanyl-l-alanine prodrug of trovafloxacin, exerted effects on proliferation and 5-bromo-2'-deoxyuridine incorporation similar to those of the parent compound. The quinolones evaluated also inhibited extracellular matrix mineralization by MC3T3-E1 cells. Treatment of confluent cultures with trovafloxacin, ciprofloxacin, or levofloxacin resulted in strong inhibition of calcium deposition, as determined on day 14 by alizarin red staining and biochemical analysis. The effect was apparent with 2.5-5 microg/ml of each of the three antibiotics tested and progressively increased to more than a 90% decline in the calcium/protein ratio with 20-40 microg/ml antibiotic concentration. Further in vivo studies are advocated to evaluate the relevance of the in vitro cytotoxicity reported here to bone healing in orthopaedic patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11117292     DOI: 10.1002/jor.1100180507

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  26 in total

1.  Do local antibiotics reduce periprosthetic joint infections? A retrospective review of 744 cases.

Authors:  Craig Winkler; Joel Dennison; Adam Wooldridge; Eneko Larumbe; Cyrus Caroom; Mark Jenkins; George Brindley
Journal:  J Clin Orthop Trauma       Date:  2017-08-24

2.  Prophylactic intrawound application of vancomycin powder in instrumented spinal fusion surgery.

Authors:  Hyun Su Kim; Sang Gu Lee; Woo Kyung Kim; Chan Woo Park; Seong Son
Journal:  Korean J Spine       Date:  2013-09-30

3.  Trovafloxacin-induced replication stress sensitizes HepG2 cells to tumor necrosis factor-alpha-induced cytotoxicity mediated by extracellular signal-regulated kinase and ataxia telangiectasia and Rad3-related.

Authors:  Kevin M Beggs; Ashley R Maiuri; Aaron M Fullerton; Kyle L Poulsen; Anna B Breier; Patricia E Ganey; Robert A Roth
Journal:  Toxicology       Date:  2015-03-05       Impact factor: 4.221

4.  Efficacy of ciprofloxacin-releasing bioabsorbable osteoconductive bone defect filler for treatment of experimental osteomyelitis due to Staphylococcus aureus.

Authors:  Jyri K Koort; Tatu J Mäkinen; Esa Suokas; Minna Veiranto; Jari Jalava; Juhani Knuuti; Pertti Törmälä; Hannu T Aro
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Tissue reactions to bioabsorbable ciprofloxacin-releasing polylactide-polyglycolide 80/20 screws in rabbits' cranial bone.

Authors:  Johanna Tiainen; Ylermi Soini; Esa Suokas; Minna Veiranto; Pertti Törmälä; Timo Waris; Nureddin Ashammakhi
Journal:  J Mater Sci Mater Med       Date:  2006-12       Impact factor: 3.896

6.  Evaluation of infection rates with narrow versus broad-spectrum antibiotic regimens in civilian gunshot open-fracture injury.

Authors:  Jordan A Woolum; Abby M Bailey; Adam Dugan; Rahul Agrawal; Regan A Baum
Journal:  Am J Emerg Med       Date:  2019-07-23       Impact factor: 2.469

7.  Probiotic Lactobacillus reuteri Prevents Postantibiotic Bone Loss by Reducing Intestinal Dysbiosis and Preventing Barrier Disruption.

Authors:  Jonathan D Schepper; Fraser L Collins; Naiomy Deliz Rios-Arce; Sandi Raehtz; Laura Schaefer; Joseph D Gardinier; Robert A Britton; Narayanan Parameswaran; Laura R McCabe
Journal:  J Bone Miner Res       Date:  2019-01-28       Impact factor: 6.741

8.  Insights on the properties of levofloxacin-adsorbed Sr- and Mg-doped calcium phosphate powders.

Authors:  Catarina F Marques; Ana C Matos; Isabel A C Ribeiro; Lídia M Gonçalves; Ana Bettencourt; José M F Ferreira
Journal:  J Mater Sci Mater Med       Date:  2016-06-14       Impact factor: 3.896

9.  Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil.

Authors:  Leonidas A Bourikas; George Kolios; Vassilis Valatas; George Notas; Ioannis Drygiannakis; Iordanis Pelagiadis; Pinelopi Manousou; Stefanos Klironomos; Ioannis A Mouzas; Elias Kouroumalis
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

10.  Better prophylaxis against surgical site infection with local as well as systemic antibiotics. An in vivo study.

Authors:  Daniel L Cavanaugh; John Berry; Seth R Yarboro; Laurence E Dahners
Journal:  J Bone Joint Surg Am       Date:  2009-08       Impact factor: 5.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.